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Fungal infections with increasing resistance to conventional therapies are a growing concern. Candida al-
bicans is a major opportunistic yeast responsible for mucosal and invasive infections. Targeting the initial
step of the infection process (i.e., C. albicans adhesion to the host cell) is a promising strategy. A wide
variety of molecules can interfere with adhesion processes via an assortment of mechanisms. Herein, we
focus on how small molecules disrupt biosynthesis of fungal cell wall components and membrane struc-
ture, prevent the localization of GPI-anchor proteins, inhibit production of enzymes involved in adhesion,
downregulate genes encoding adhesins and competitively inhibit receptor interactions. As a result, adhe-
sion of C. albicans to host cells is reduced, paving the way to new classes of antifungal agents.
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The genus Candida includes about 200 different species, with only a few species being opportunistic pathogens of
humans, of which Candida albicans is the most frequently encountered clinically [1]. It is a commensal colonizer in
humans and exists in the gastrointestinal and genitourinary tracts: it is a normal component of the body microbiota
where it is found predominantly on mucosa [2]. However, it is known to cause infections when the host becomes
immunocompromised. These infections can be superficial and affect the skin (cutaneous candidosis), the mucous
membrane of the oral and vulvovaginal cavities, and the fingernails (paronychial and onychial candidosis) [3]. C.
albicans infections can also be invasive, entering the bloodstream and disseminating to internal organs. Factors that
contribute to fungal invasion include: surgery (especially abdominal), burns, long-term stay in intensive care unit,
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Figure 1. Candida albicans adherence and
morphogenesis lead to biofilm formation and tissue
invasion: adherence of yeast cells to epithelial cell
surface is the initial step for C. albicans colonization;
subsequent yeast-to-hypha transition facilitates biofilm
formation, tissue invasion and spread of systemic
infection.
Adapted with permission from [12].
disease (e.g., cancer and HIV infection), previous administration of broad-spectrum antibiotics and immunosup-
pressive agents, antineoplastic chemotherapy, immunosuppression prior to organ transplantation, haemodialysis
and central venous catheters [4].
There are three main factors that contribute to the high mortality of invasive fungal infections. First, since
conventional microbiological approaches for fungal identification are insensitive, nonspecific and laborious, a
trustworthy, timely diagnosis is challenging. Second, the clinical signs and symptoms of an invasive fungal infection
may not be present until the infection is at an advanced stage [5]. Third, and most significantly, current antifungal
therapies often lack selectivity; the overuse of these drugs have led to the development of antifungal resistance [6].
Antifungal resistance can develop in different ways, depending on the mode of action of the antifungal drug.
Resistance mechanisms include reduction in the intracellular accumulation of the drug, decrease in the affinity for
the target and counteraction of the drug effect (e.g., overexpression of genes that encode the target proteins) [7]. C.
albicans has developed resistance to common antifungal drugs used to treat fungal infections, such as the azoles [8],
echinocandins [9] and polyenes [10].
C. albicans: infection process
C. albicans relies on a wide-range of virulence factors to infect its host, and these are discussed in great detail in
numerous reviews [11–19]. Infections are the invasion and multiplication of pathogenic microbes causing disease.
C. albicans is a dimorphic fungus: it can exist in the ovoid-shaped budding yeast form, which transitions to the
branching filamentous hyphae form [13,14]. To infect its host, C. albicans yeast cells adhere to the host cell using
adhesins [15], the best studied of which are the agglutinin-like sequence proteins [16] and Hwp1 [20]. After initial
adherence, contact with the host cell triggers the yeast-to-hypha transition, directed growth of the hypha occurs
through thigmotropism. Invasion into the host cell is then facilitated by invasins, adhesion and physical forces, and
occurs via endocytosis or active penetration (Figure 1) [12,17,21]. There is a strong correlation between adherence
and ability to colonize and cause disease. For example, C. albicans is highly adherent and implicated in a wide range
of diseases, while species such as Candida krusei and Candida glabrata adhere more poorly and are less frequently
implicated in disease. Biofilm formation enables the fungi attachment to biotic or abiotic surfaces [18], including
medical devices [19].
To prevent C. albicans infection, all the stages of this multistep process may be targeted. Recently, research
toward new antifungal agents has aimed at the selective targeting of virulence mechanisms as opposed to the killing
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of the pathogen, which may increase the selection pressure for development of drug resistance. Thus, strategies
seeking the inhibition of C. albicans filamentation (i.e., morphological transitions between single-cell budding
yeast and filamentous forms) or biofilm formation have received considerable attention and have been reviewed
elsewhere [18,22,23]. This review will focus on the anti-adhesion approach, which aims to block the adhesion of
the pathogen to the host cell as the first step in the pathogenesis of microbial infections. Interestingly, it is often
found that compounds impairing fungal adhesion also have an effect on filamentation or biofilm formation. In this
context, a vast amount of research has been carried out into elucidating host–pathogen relationships [24–26].
Anti-adhesion strategy in fungal pathogens
Adhesins are the molecular mediators of adhesion: they are often cell-surface biomolecules, usually (manno)proteins
that allow for the attachment of the microbe to host cells or surfaces. Fungal pathogens display a large variety of
adhesins on their surface, so they can adhere to several cell types within the host [27–29] and to numerous ligands in
various host sites, such as biological fluids, extracellular membrane and basement membranes [30]. The information
available on fungal adhesins is more limited than on bacterial ones [31]. This may have contributed to anti-adhesive
therapies for bacterial infections having been investigated more extensively than fungal ones [32]. Fungi are complex
eukaryotic cells that have structurally unique cell walls, with each species displaying distinctive glycan polymers
and proteins [33]. The development of high-affinity ligands is enabled by a detailed knowledge of protein structure.
Recently, some fungal adhesins in Aspergillus fumigatus (e.g., FleA) have been identified [34,35], fully characterized
and crystal structures have been solved [36]. Hence, high-affinity anti-adhesion ligands for this adhesin have been
developed [37], proving this approach is also possible for fungal pathogens. The limited number of x-ray crystal
structures available for C. albicans adhesins has hampered a focused design approach to anti-adhesion agents. Thus,
the majority of studies dealing with C. albicans inhibition of adhesion discussed herein are carried out without
targeting a specific protein.
Disruption of C. albicans adhesion by antibodies & biomolecules
The interaction of C. albicans with mucosal surface is essential for fungal colonization [38–40]. Early studies pointed
to the role of cell surface glycoconjugates as mediators of adhesion for C. albicans. Sandin et al. showed evidence for
mannose-mediated adhesion to buccal epithelial cells (BECs) [41]. Concanavalin A (ConA), a lectin that recognizes
mannose and glucose, inhibited the adherence of pretreated yeasts to BECs. This suggests that ConA is binding to
and blocking the mannose-containing receptors on the yeast surface or mannose moieties of the indigenous lectin
associated with the yeast cell surface. ConA also inhibited the adhesion of pretreated BECs with nontreated yeasts.
This result indicates that mannose-containing moieties on the buccal cell surface could be acting as receptors for the
C. albicans [41]. Also, the presence of α-D-methyl mannoside in the incubation medium during the assay inhibited
adhesion of C. albicans to the BECs. Critchley and Douglas investigated the effect of several lectins and sugars
on the adhesion of C. albicans to buccal and vaginal epithelial cells [42]. The adherence of most C. albicans strains
were inhibited by L-fucose and winged-pea lectin (specific for L-fucose), suggesting that a glycoside containing
α-L-fucosyl residues might function as a receptor for these strains. Other lectins, such as wheat-germ agglutinin
(specific for N-acetyl-β-D-glucosaminyl residues) or peanut lectin (specific for D-galactosyl residues) had little
effect on the adherence of these strains. In contrast, the adherence of one C. albicans strain was efficiently inhibited
by N-acetyl-D-glucosamine and wheat-germ agglutinin and was unaffected by winged-pea lectin and peanut lectin.
Interestingly, the adhesion of all strains in this study were significantly enhanced by ConA lectin. It was postulated
that this effect is due to the fact that ConA has multiple-binding sites and can therefore promote adhesion by
cross-linking, acting as bridges between α-D-mannosyl residues on the yeast and epithelial surfaces.
Cell surface glycoconjugates on human BEC have also been investigated as possible adhesion receptors for C.
albicans. Brassart et al. [43] studied the ability of soluble glycopeptides and oligosaccharides to inhibit the adhesion
of yeast to exfoliated cells. Preliminary studies showed that fucose played a role in inhibiting the adhesion process.
Using human milk oligosaccharides as probes, the minimal requirement for activity was found to be the Fucα(1-
2)Galβ determinant. This study concluded that this disaccharide, found in cell surface glycoconjugates, may act as
a part of a complex adhesion mechanism, which possibly requires multireceptor specificities. In addition, salivary
fucosylated glycans and glycoproteins were also able to block C. albicans adhesion to BEC [44,45].
Monoclonal antibodies (mABs) have also been investigated as inhibitors of C. albicans adhesion. MABs raised
against C. albicans cell wall components inhibited whole yeast cell binding to BEC [46]. Also, mABs generated
against mannosylated C. albicans adhesins or secreted aspartyl proteases were used in vivo in a rat model of vaginal
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candidiasis and demonstrated significant reductions of fungal burden [47]. mABs directed against the extracellular
matrix proteins: collagen, laminin and fibronectin, reduced the adherence of C. albicans to HEp-2-cultured cells [48].
The anti-adhesion ability of glucosamine and other simple sugars had been previously reported [49]; a combination
of this sugaramine with anticollagen IV antibody reduced yeast-HEp-2 adherence by approximately 70%.
Disruption of C. albicans adhesion by small molecules
The majority of research on fungal anti-adhesion ligands based on small molecules has focused on C. albicans. Small
molecules may display different mechanisms to inhibit the adhesion of fungi to host cells, although in most cases
their mode of action is unknown. It is often not clear if the disruption in adhesion caused by these compounds is
due to specific interactions with a biomolecular target or is a consequence of nonspecific effects (i.e., hydrophobic
and/or electrostatic interactions). It is also important to note that an apparent reduction of adhesion may be
observed if the compounds have fungicidal activity; for this reason, it is should be ensured that anti-adhesion assays
are carried out well below the concentration range at which the compounds are toxic to the yeast cells. Compounds
from both synthetic and natural sources have been tested for their anti-adhesive properties toward C. albicans.
A range of adherence assays have been used to test the inhibition of adherence of the small molecules outlined
in the following sections. The differences in experimental setup and quantification methods employed in these
assays can complicate standardization and the comparison of the anti-adhesion activity across the various studies.
The main assays involve measuring the adhesion of C. albicans to different substrates: suspended BECs; human cell
monolayers; and polystyrene, which provides a useful model for abiotic surfaces. The general procedures for these
assays are summarized below.
To determine the ability of compounds to inhibit the adhesion between C. albicans and suspended BEC the
following steps are followed. C. albicans were harvested, washed and re-suspended in phosphat-buffered salin (PBS).
The number of yeast per milliliter was determined using a hemocytometer. BEC were collected from volunteers,
suspended in a PBS solution and washed three- to four-times by centrifuging. Solutions of BEC and C. albicans
were mixed using volumes that ensured a higher quantity of yeast than BEC, usually 50–100: one ratio of yeast
to BEC. This mixture was incubated at typically 30–37◦C for 1–3 h. Cell were then harvested on polycarbonate
filters/nylon filter paper, washed with PBS to remove unattached yeast, air dried on slides and stained using Gram
stain or crystal violet. The number of yeast attached to 50–200 BEC were counted using light microscopy. This
number was compared with a control, which received no treatment. All assays were repeated two- to four-times. The
potential anti-adhesion compounds may be added at different times throughout the experiment: in the exclusion
or prelabeling assay compounds were added to the yeast before being mixed with BEC; in competitive assay
compounds, yeast and BEC are all mixed together; or in displacement assay initial adherence between yeast and
BEC was allowed and then compounds were added.
To determine the ability of compounds to inhibit the adhesion between C. albicans and a cell monolayer
the following steps are followed. A human cell line (generally epithelia) was grown until they formed confluent
monolayers in medium at 37◦C in cell culture plates. C. albicans were treated with potential anti-adhesion
compounds in medium at 30◦C overnight without shaking. A known amount of yeast cells were added to the
established monolayers of human cells. This was incubated at 35–37◦C for 45 min to 2 h in 5% (v/v) CO2,
monolayers were washed twice and covered with warm sabouraud dextrose agar. Yeast colonies appearing after
18–48 h at 30◦C were counted and compared with the control. The experiments were conducted in triplicate.
To determine the ability of compounds to inhibit the adhesion between C. albicans and a polystyrene surface, the
following steps are followed. C. albicans cells were added to 96-well polystyrene-coated cell culture plates and were
allowed to adhere in the presence of potential anti-adhesion compounds at 37◦C for 90 min and 24 h in a temperature
regulated incubator. Cells were washed with PBS to remove any cells not adhering to the plates. Adhesion
was then quantified using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) metabolic assay,
AlamarBlue cell viability assay, by adding crystal violet and determining absorbance at 570–590 nm, or through
count of colony-forming units and were compared with a control. In some cases, the potential anti-adhesion
compounds were added to the plates prior to the C. albicans. The compounds were allowed to coat the plate for
12 h at 37◦C and then the yeast cells were added to the plates.
Some of the processes involved in yeast adhesion that these molecules target or interfere with include:
• The biosynthesis of cell wall components;
• The localization of GPI-anchored proteins;
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Figure 2. Disruption of the biosynthesis of cell wall components. (A) Structure of the small molecule inhibitor 1 of
β-1,6-glucan biosynthesis; (B) microscopic images of untreated Candida albicans cells; (C) microscopic images of C.
albicans cells treated with compound 1.
Adapted with permission from [51].
• Inhibition of degradative enzyme production;
• Downregulation of genes that encode for adhesins;
• The disruption of the fungal cell membrane structure;
• The use of small molecules that competitively inhibit the interaction between the fungal adhesin and the host
cell receptors.
Some examples relevant for each classification will now be presented.
Disruption of the biosynthesis of cell wall components
β-1,6-glucan is an essential component of fungal cell walls, in particular in C. albicans, where it has been reported
to retain cell wall proteins. Compound 1 has been identified as an inhibitor of β-1,6-glucan biosynthesis. This
resulted in the release of cell wall proteins, impacting in the yeast virulence (Figure 2). It was shown that the
adhesion of C. albicans to a monolayer of cancerous human lung epithelial cells was significantly inhibited in the
presence of compound 1. At concentrations of 0.1 μg/ml compound 1 reduced adherence by approximately 30%,
while at concentrations of 1 μg/ml adherence was reduced by approximately 80% [50].
Anti-adhesion tests of fluconazole (2) (Figure 3), a well-known, bis-triazole antifungal drug, were performed by
Darwazeh et al. [52]. They explored the effect of systemic fluconazole intake on C. albicans adhesion to BEC obtained
from healthy volunteers on systemic fluconazole therapy. It was found that the fluconazole significantly reduced the
number of yeasts adhering to BEC. A 48.7% reduction in adhesion was observed during treatment compared with
levels prior to commencement of fluconazole therapy. Several other studies have also shown significant reduction
of adherence of C. albicans isolates to denture acrylic and BEC after treatment with fluconazole [53–55]. It is known
that 2 inhibits the production of lanosterol 14-α-demethylase, an enzyme involved in the biosynthesis of ergosterol,
the largest sterol component of the fungal cell membrane. This affects the cell surface composition of C. albicans
and hence the ability to adhere to BEC.
Several tetrazole compounds were reported to have anti-adhesion properties against C. albicans. Compound 3
(Figure 3) was found to be the most active of a series of 2,5-disubstituted tetrazoles that were tested as inhibitors of
C. albicans adhesion. This compound efficiently reduced the adherence of C. albicans to Caco-2 cells by 86%, at
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Figure 3. Examples of small molecules that disrupt the biosynthesis of cell wall components. Structures of triazole
and tetrazole compounds, including fluconazole (2), that show anti-adhesive properties toward Candida albicans by
disrupting cell wall biogenesis.
16 μg/ml. Compound 3 exhibited minor cytotoxicity to Vero epithelial cells, where the viability of the mammalian
cells was only reduced by 13–14% at the highest concentrations (64–256 μg/ml) [56]. More 2,5-disubstituted
tetrazoles were tested by Staniszewska et al., compound 4 (Figure 3) reduced the adhesion of C. albicans to Caco-2
(human epithelial colon carcinoma cells) monolayer by >60% at 0.0313 μg/ml. Compound 4 has a CC50 (50%
cytotoxic concentration) of 16 μg/ml against Caco-2, and is nontoxic at 0.0313 μg/ml [57]. Tetrazole derivatives
with pyrrolidine scaffolds were also evaluated. Compound 5 (Figure 3) and other derivatives were tested for their
ability to prevent C. albicans adhesion to TR-146 (buccal mucosa) cell-line monolayer. At high concentration,
compound 5 was toxic to mammalian Vero cells (100% reduction of viability at 129 μg/ml), but its cytotoxicity
decreased by fourfold at lower concentrations. Compound 5 reduced the adherence of the yeast most efficiently
(over 98% reduction at 16 μg/ml). However, at that concentration, the compound caused yeast cell death, so it is
likely that this produced the observed reduction in cellular adhesion [58].
Disruption in the localization of GPI-anchored proteins
GPI-anchored cell wall mannoproteins are required for the adhesion of pathogenic fungi, such as C. albicans,
to human epithelium. Tsukahara et al. [59] discovered an isoquinoline derivative, compound 6, that inhibits the
localization of cell wall GPI-anchored mannoproteins in Saccharomyces cerevisiae and C. albicans. Compound 6
prevented the adhesion of C. albicans cells to a monolayer of rat intestinal epithelial cells (Figure 4). The molecular
target of this compound was found to be the protein product of a novel gene, GWT1. They suggest that GWT1
protein may be involved in the synthesis of GPI, transportation of GPI-anchored protein within the cell and the
relocation of the GPI-anchored protein to the fungal cell wall.
Inhibition of degradative enzyme production
Extensive research on the anti-adhesive properties of sulfone derivatives has been conducted in Staniszewska’s
laboratory [60,61]. Compounds 7 and 8 (Figure 5) were evaluated against the adhesion of a wild-type C. albicans
strain and three mutant strains (sap9, sap10 and sap9/10) to a monolayer of Caco-2 cells. First, the fungi
were pretreated with the sulfone derivatives. Compound 7 significantly altered the adherence properties in a
concentration-dependent manner. Adhesion of the wild-type C. albicans was 10.8-fold lower than the nontreated
controls at a concentration of 8 μg/ml, and was 5.2-fold lower at a concentration of 16 μg/ml. The mutant strains
displayed a larger inhibition of adhesion. When the yeast cells were post-treated with the sulfone derivatives at
16 μg/ml, there was a very significant reduction of adhesion, ranging from 44.0- to 112.1-fold [60]. Compound 8
also exhibited reduced adhesion, but to a lesser degree than compound 7.
In another study, structurally similar sulfones were tested against C. albicans wild-type and mutant strains efg1
and cph1, which lack morphological transitionality. The various strains showed different susceptibility to the
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Figure 4. Disruption in the localization of GPI-anchored proteins. Structure of isoquinoline derivative 6 and graph
showing the effect of 6 on the adherence ability of Candida albicans.
Adapted with permission from [59].
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Structure of sulfone-derivatives that have anti-adhesive
properties toward Candida albicans.
sulfone derivatives. Compound 9 and the previously evaluated sulfone derivatives 7 and 8 (Figure 5) were also
tested for their ability to inhibit the adhesion to epithelial cells. At concentrations of 8–16 μg/ml, pretreatment
of the cells with sulfones 7 and 9 did not inhibit the adhesion of all the C. albicans strains tested. However, at the
highest concentration (16 μg/ml) sulfones 7 and 9 inhibited attachment of the wild-type C. albicans to the Caco-2
monolayer. Compound 8 affected the adhesion of the tested strains significantly at all the concentrations, with the
best results at a concentration of 16 μg/ml in 62% of strains [61].
More studies were carried out on compound 7 and a new β-ketosulfone compound 10 (Figure 5). The yeast cells
were pretreatment with the β-ketosulfone (16 μg/ml), which significantly inhibited the adhesion of C. albicans
to the Caco-2 monolayer, showing a reduction in adhesion of 49.46% (1.97-fold reduction compared with the
control) [62].
These sulfone derivatives successfully inhibit degradative enzyme production, for example secreted aspartyl
proteases, which have been associated to the enhancement of adhesion processes by the degradation of extracellular
matrix and host surface molecules, allowing penetration into host tissues. SAP2 is downregulated in the presence of
these sulfone derivatives. The ability of these compounds to inhibit enzyme production may influence the adhesion
of C. albicans to host cells.
Downregulation of genes that encode adhesins
Numerous natural products have been tested for their anti-adhesive properties toward C. albicans adhesion. These
include polyphenols such as curcumin, pyrogallol, magnolol and honokiol, and anthraquinone derivatives such as
purpurin, alizarin, chrysazin and emodin. These compounds’ mechanism of action involves the downregulation of
C. albicans adhesin genes.
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that have been shown to inhibit the adhesion of Candida albicans by downregulation of genes that encode adhesins..
Polyphenols
Curcumin (11) (Figure 6) is a yellow polyphenol produced by the rhizome of Curcuma longa, or turmeric, plants.
This compound possesses a wide range of pharmacological properties. In this work, curcumin and curcumin
extracts were evaluated for antifungal activity against numerous fungal strains. The ability of curcumin to inhibit
the adhesion of Candida spp. to human BEC was determined. Curcumin (64 μg/ml) inhibited the adhesion of C.
albicans to BEC by >50% [63].
In another study, fourteen polyphenols were tested for their antifungal properties. From these compounds,
11 and pyrogallol (12) (Figure 6) showed the best antifungal properties. These compounds were also evaluated
for their anti-adhesion properties at SMIC50 (sessile minimum inhibitory concentrations), 50 μg/ml for 11 and
39.06 μg/ml for 12. The precoating of coverslips with 11 reduced the ability of C. albicans to adhere by 55.3%,
while 12 only reduced adhesion by 15.63%. Compound 11 resulted in the downregulation of the expression of Als3
and Hwp1 adhesins, whereas 12 showed no significant downregulation of the adhesins following treatment [64].
In an effort to increase the activity of 11, curcumin-silk fibroin nanoparticles were developed using silk fibroin
(insoluble protein present in silk) as the carrier. These nanoparticles could inhibit the adhesion of C. albicans to
pulmonary epithelial cells significantly compared with curcumin alone [65].
Magnolol (13) and honokiol (14) (Figure 6) are lignans found in the bark of species of magnolia. These
compounds significantly inhibited the adhesion of C. albicans to a monolayer of immortalized rat hepatic stellate
cells in a concentration-dependant manner, ranging from 4 to 32 μg/ml; for example, at 4 μg/ml, adhesion was
reduced by approximately 15–20% while at 32 μg/ml, adhesion was reduced by >95%. The viability of the
mammalian cells were not affected by compound 13 or 14 at the concentration range studied [66]. Compounds 13
and 14 both produced significant downregulation of HWP1, ALS3 and ECE1 genes which encode adhesins.
Anthraquinone derivatives
Purpurin (15) (Figure 6) is a naturally occurring red/yellow dye from the roots of the Rubia tincorum, or mad-
der plant. The anti-adhesion properties of purpurin were evaluated at a range of concentrations (10–40 μg/ml).
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albicans by disruption of the fungal membrane.
It was found that 15 has an effect on adhesion of C. albicans in a dose-dependent manner. Also, expressions of
adhesion-related genes, namely ALS1, EFG1 and HWP1 were decreased in comparison with the control [67].
Alizarin (16) (Figure 6) is a red dye derived from the roots of plants of the madder genus. Chrysazin (17) (Figure 6)
is a synthetic derivative of alizarin. 16 and 17 (2–10 μg/ml) appear to inhibit cell adhesion, biofilm formation and
hyphal development in C. albicans by regulating hypha-specific genes [68]. 16 also downregulated the expression
of several hypha-specific and biofilm-related genes (ALS3, ECE1, ECE2 and RBT1), which affect the adhesive
properties of the yeast. The toxicities of compounds 16 and 17 were examined using a nematode model by
determining their survival after 4 days. This showed that both 16 and 17 are less toxic then fluconazole.
Emodin (18) (Figure 6) is a natural secondary plant product, originally isolated from the rhizomes of Rheum
palmatum, or Chinese rhubarb, plants. 18 has been tested for its anti-adhesion properties to polystyrene microtiter
plates (3–400 μg/ml). In this study, 50 strains of C. albicans isolated from vaginas of women in diverse age
categories were tested. It was found that this compound could inhibit the adhesion of C. albicans to the plates
in 30 of the strains, while the adhesion of only 15 of the strains were affected by 18 when the biofilm had been
established [69]. Due to the structural similarities to purpurin and alizarin, it is assumed that this compound may also
cause downregulation of genes relating to adhesion. Interestingly, emodin added to Candida culture also inhibited
the phosphorylation of many cellular proteins, leading to the inhibition of protein kinase CK2, which governs the
interactions of C. albicans with endothelial and oral epithelial cells in vitro and virulence during oropharyngeal
candidiasis.
Disruption of cell membrane structure
Quaternary ammonium compounds
Many quaternary ammonium compounds have been found to have anti-adhesive properties against C. albicans and
some of their structures are shown in Figure 7. Nonantibiotic, antimicrobial agents (cetrimonium bromide [19],
cetylpyridinium chloride [20] and dequalinium chloride [21]) at sublethal concentrations were shown to reduce
the adherence of C. albicans to human BEC in vitro [70].
Research has also been carried out on surfactants 22–25 to test their anti-adhesive properties against C. albicans:
cetyltrimethylammonium chloride (22), SDS (23), N-hexadecyl-N–N’-dimethyl-3-ammonio-1-propane-sulfonate
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Structures of alanine-derived gemini quaternary ammonium salts; (B) structures of medium alkyl chain cationic
lipo-oxazole and lipo-benzamide compounds; (C) structure of double-headed cationic surfactants.
(HPS; 24) and octylphenoxypolyethoxyethanol (Triton X-100; 25). All the surfactants tested displayed a decrease
in the number of yeasts adhered to BEC; however, the greatest reduction was obtained by 22 (37.1–53.8%) and
24 (32.7–43.5%) in all concentrations tested (0.3–3 μg/ml) and for 23 (28.2–35.8%) and 25 (28.8–30.1%) at
the concentrations of 1.5 and 3 μg/ml, respectively [71].
The principal factor which accounts for inhibition of adherence is the denaturation of adhesins on C. albicans
by the cationic charge of these surfactants. Additional factors include the disruption of the fungal membrane and
steric interference on the approach of the microbial cell to the epithelial cell (long hydrophobic chains decrease
contact between microbial cell and the substrate). Alteration of cell surface hydrophobicity and cell zeta potential
have also been suggested to contribute to the observed activities [71].
A collection of alanine-derived gemini quaternary ammonium salts featuring alkyl chains and spacers of different
lengths was tested for inhibition of adherence of C. albicans to polystyrene and silicone surfaces (structures of two
examples are shown in Figure 8, compounds 26 and 27). The deposition of gemini quaternary ammonium salts on
the polystyrene plate inhibited yeast cell adhesion, with 50% reduction exhibited only at the highest concentrations
of 110 μg/ml (26) and 117 μg/ml (27). Both compounds also exhibited anti-adhesive properties to the silicone
catheter, with compound 27 showing slightly better activity [72].
Cationic lipo-oxazoles containing hydrocarbon chains (C6–C13) and a quaternary ammonium group were
evaluated for their antifungal, anti-adhesion and biofilm inhibition properties. Heptyl and octyl chain analogs
showed promising antifungal activity. Cationic lipo-oxazole compound 28 (Figure 8B) demonstrated about 60%
reduction in adhesion to polystyrene surfaces at a concentration of 12.5 μg/ml compared with the control. Also the
cytotoxicity of 28 was determined in mammalian cells, and IC50 values of 13.1–45.2 μg/ml were calculated [73].
This cationic agent reportedly reacts with the phospholipid component in the cell membrane, thereby producing
membrane distortions often leading to a complete loss of structural organization of the cells.
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The same research group then evaluated lipo-benzamide compounds fused with varying lengths of hydrocar-
bon chains (C2–C18) for antifungal activity against C. albicans. Quaternary ammonium group containing C9
hydrocarbon chain derivative 29 (Figure 8B) inhibited the adhesion of C. albicans to polystyrene surfaces in a
concentration-dependent manner. In particular, at 12.5 μg/ml compound 29 inhibits 90% adhesion compared
with the control [74].
Double-headed cationic surfactants with varying hydrocarbon chain length (n-C13H27 and C15H31) were
synthesized and their antifungal properties were investigated. The ability of these surfactant coatings to inhibit
fungal adhesion was tested using different surfaces: polystyrene, silicone, glass and stainless steel. The adhesion
studies were focused on C14(DAPACl)2 (30), C16(DAPACl)2 (31), C14(TAPABr)2 (32) and C16(TAPABr)2 (33)
(Figure 8C). The adhesion of C. albicans to polystyrene was not greatly affected by the tested compounds,
with the chlorides showing slightly better results. C. albicans adhesion to silicone catheters was reduced by C16
dicephalic surfactants 31 and 33. Significant reduction (∼50%) was observed for C16(TAPABr)2 33 at 100 μM
(or 61.5 μg/ml). Unexpectedly, C14 compounds (30 and 32) resulted in an increase of C. albicans adhesion. Both
chlorides (30 at 47 μg/ml and 31 at 50 μg/ml, 100 μM) drastically reduced the adherence of C. albicans to the
stainless steel surface. All of these dicephalic surfactants had similar results in the adhesion assays to the glass surface
and for most cases, significant reduction in the amount of adherent cells was only achieved at concentrations at
high as 400 μM (199–246 μg/ml) [75]. Interestingly, these compounds did not cause DNA leakage from the C.
albicans cells, with the exception of C14(DAPACl)2 (31). Therefore, the mode of action of dicephalic surfactants
does not involve cell lysis. Instead, the dicephalic surfactants impacted reactive oxygen species (ROS) production
and accumulation of lipid droplets.
Nonantibiotic antimicrobial agents
Nonantibiotic antimicrobial agents, compounds which affect multiple cellular targets in a nonspecific way, have a
similar effect as the quaternary ammonia compounds on the adhesion of C. albicans. Several studies have shown
that chlorhexidine gluconate (34) (Figure 9) is able to reduce the adhesion of C. albicans cells to BEC at very low
concentrations (as low as 0.00005% v/v or 0.5 μg/ml) [70,76–78]. In recent years, in fact, chlorhexidine is often used
as a positive control when testing the adhesive properties of other compounds [79–82]. This antifungal impairs the
integrity of the cell wall and the plasma membrane entering the cytoplasm resulting in leakage of cell contents and
leading to cell death.
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Another known antimicrobial agent, taurolidine (35) (Figure 9), was analyzed for its anti-adhesive properties. 35
at 2% concentration is usually used to prevent infections in catheters. It has been shown to reduce the adherence
of C. albicans (vaginal isolate) to buccal and uroepithelial cells at concentrations below 0.1% (or 1000 μg/ml) [83].
Brolene is a nonantibiotic, antimicrobial preparation, which contains propamidine isethionate (36) as the
antimicrobial active agent and benzalkonium chloride (37) (Figure 9) as a preservative, both of which are cationic
agents. Two strains of C. albicans, including one clinical isolate from an oral infection, were employed in this
study. At both concentrations examined (10 and 100% w/v, or 0.1 and 1 g/ml), brolene significantly reduced the
adherence of C. albicans to BEC. These effects were observed for both strains, when either the BEC or yeast were
treated. Reductions in adherence ranged from 25.91 to 76.02% [84].
Terpenes & terpenoids
Terpenes are a large and diverse class of natural compounds produced by numerous plants and insects. The amyrins
are a family of natural triterpenes, which include α-, β- and δ-amyrin. The antifungal activity of these natural
compounds, along with synthetic derivatives, was evaluated against Candida species. Of the compounds tested, α-
and β-amyrin formiate (38 and 39) (Figure 10) and α- and β-amyrin acetate inhibited the growth of all the tested
Candida species at concentrations of 30–250 μg/ml. In particular, 38 and 39 at 60 μg/ml inhibited the adhesion
of C. albicans to BEC by 65.3% [85].
Limonene (40) is a nontoxic (up to 15 g/day), cyclic monoterpene, which has been shown to inhibit adhesion
of C. albicans to abiotic surfaces at concentrations 0 of 0.163–2.7 mg/ml [86]. Specifically, limonene inhibited the
development and maturation of biofilms by 50% at concentrations of 0.245, 0.163 and 1 mg/ml, respectively, and
inhibited adhesion by 90% at 0.681 mg/ml. Proteomic analysis suggests that 40 inhibits C. albicans growth by cell
wall/membrane damage inducing oxidative stress that causes DNA damage, which leads to apoptosis.
Terpenoids are a large and diverse family of natural compounds derived from terpenes, comprising approximately
60% of known natural products. Two abietane diterpenoids isolated from Salvia austriaca, or Austrian sage, taxodone
(41) and 15-deoxy-fuerstione (42) (Figure 10) were tested in C. albicans. 41 was found to significantly limit the
degree of C. albicans adhesion to polystyrene microtiter plates by about 41% at both concentrations of 15.6 and
31.3 μg/ml. Biofilm formation was also inhibited by 75.5 and 76.4% at both concentrations. 42 did not perform
as well as taxodone, inhibiting the adhesion of C. albicans by 38.3% at 125 μg/ml [87]. It has been proposed
that abietane diterpene can cause hydroxyl radical formation, which may cause leakage of the cell contents by
disruption of the fungal cell membrane. For terpenoids, the mechanism of action is not fully understood, however,
it is postulated that these lipophilic compounds disrupt the cell membrane and that their functional groups affect
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enzyme structure. It has also been suggested that terpenoids inhibit the synthesis of 1,3-β-D-glucan, a component
of the fungal cell wall [85,87]. All of these processes impact the adhesion of C. albicans.
Blocking the interaction of fungal adhesins & host cell receptors
The inhibition of the interactions between fungal adhesins and host cell receptors can be attempted through several
approaches, including: competitive binding with analogs of host cell receptors; binding to specific lectins; use
of anti-adhesion antibodies; modulations of adhesins or host cell receptors induced by drugs, enzymes or other
substance; use of inhibitors of enzymes involved in biosynthesis of the cell wall components [88]. Some of these
processes overlap to some extent with the anti-adhesion mechanisms discussed in previous sections.
Heterocyclic derivatives
The nitro-benzene compound 43 (Figure 11), which possesses various structural moieties present in known
antibiofilm agents, was identified by Marc et al. [89]. Compounds containing a N-(oxazolylmethyl)-thiazolidinedione
scaffold were found to be selective inhibitors of C. albicans biofilm formation. In silico screening suggested that
the compounds could act by binding to the C. albicans Als surface proteins, especially Als1, Als3, Als5 and Als6,
which are well-known adhesion proteins. The binding pocket of these proteins have a large percentage of polar
amino acids, which could account for their ability to form polar interactions with various ligands, such as the
N-(oxazolylmethyl)-thiazolidinediones present in compound 43.
More recently, in silico screening identified 24 potential compounds with the ability to interact with Als3 adhesin
of C. albicans. Als3 is specific to hypha and hence is involved in the invasion process. Biological assays narrowed
the compounds down to five with the ability to inhibit the adhesion and biofilm formation of C. albicans to abiotic
surfaces at concentrations between 1 and 512 μg/ml. The best performing compound 44 shows hydrogen-bonding
interactions with lysine, tyrosine and aspartic acid residues in the binding site of the protein, along with two π–π
interactions with tyrosine residues (Figure 12). This compound reduced the adhesion by 96.00% and biofilm
formation by 95.33% to the abiotic surface [90].
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Carbohydrate derivatives
As discussed previously, early reports indicate that some C. albicans adhesins recognize and bind to a broad range of
cell surface glycans and carbohydrates [41–45,49]. In these studies, it was found that not only complex oligosaccharides,
but also mono and disaccharides (e.g., α-D-methyl mannoside [45] [41], L-fucose [46] [42], N-acetyl-D-glucosamine
[47] [49], Fucα(1-2)Galβ moiety [48] [43], structures shown in Figure 13) can affect the adhesion process of C.
albicans to human buccal BEC.
More complex carbohydrate-based compounds have been found to participate in the adhesion process of C.
albicans. Glycosphingolipids in particular can act as adhesion receptors for yeasts. C. albicans bound specifically
to lactosylceramide (49) (Galβ(1-4)Glcβ(1-1)Cer; Figure 14), and required the terminal galactosyl residue for
binding [91]. It has also been reported that C. albicans yeast form expresses an adhesin that binds to asialo-GM1 (50)
(gangliotetraosylceramide: βGal(1-3)βGalNAc(1-4)βGal(1-4)βGlc(1-1)Cer), a glycosphingolipid displayed on the
surface of human BEC (Figure 14). It was found that the minimal carbohydrate sequence required for binding was
βGalNAc(1-4)βGal [92]. This disaccharide and synthetic derivatives have been shown to inhibit in vitro binding of
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BEC to the adhesin and the yeast cells. Fimbrigal-P (51) (octyl-O-(2-acetamido-2-deoxy-β-D-galactopyranosyl)-
(1-4)-2-O-propyl-β-D-galactopysanoside) is a propyl-derivative of this disaccharide (Figure 14). The in vivo efficacy
of 51 was evaluated in a rat model for oral candidiasis. This compound was able to reduce the oral fungal burden,
making it a promising candidate for the prevention and treatment of microbial infections in which the pathogen
relies on the βGalNAc(1-4)βGal disaccharide to establish adherence [93].
Recently, a small library of aromatic glycoconjugates was evaluated for activity as C. albicans adhesion in-
hibitors [94]. This study showed that divalent galactoside (52) (Figure 14) could inhibit adhesion up to 80% when
the yeast were pretreated with the glycoconjugate. Also, this compound could displace up to 50% of yeast already
adhering to BEC at a concentration of 0.1 mg/ml. In a later study, a second generation of divalent galactosides
were assayed for anti-adhesion activity. Compounds with norbornene core such as 53 (Figure 14) presented activity
comparable with lead compound 52, highlighting the importance of the presentation of the two galactosides toward
inhibition of C. albicans adhesion [95].
Unknown/other mode of action
Thiazole (54) and diazanaphthalene (55) functionalities are also present in compounds that exhibit anti-adhesion
activity and their structures are shown in Figure 15. Compound 54 inhibited adhesion of C. albicans to human
BEC by 75% at MIC values (1–4 mg/ml for most strains) [96]. This antifungal was also tested on Cryptococcus
strains. Its mode of action is related to the interference with the antioxidant system and accumulation of superoxide
radicals. These destructive events prevent the fungi from employing its virulence factors, therefore inhibiting C.
albicans adhesion. However, it is not clear if this is a consequence of the fungicidal effect exerted by 54 at MIC.
Silmitasertib (CX-4945) (55), an antitumor drug which is a selective inhibitor of protein kinase CK2, has been
found to have antifungal properties. It effectively inhibited the adhesion phase of the biofilm formation process of
C. albicans by 42% at the concentration of 62.5 μg/ml (1/4 MIC) [97]. The mode of action of this compound is
unknown, but could prevent possible cancer-associated candidiasis.
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Statins are widely used for the control of cholesterol, and function by inhibiting the action of 3-hydroxy-3-
methylglutaryl-CoA reductase. In C. albicans, statins reduce the synthesis of ergosterol and the abundance of a
number of adherence associated proteins (e.g., Cip1p, Pst2p and ABC efflux transporter), leading to a reduction in
adherence to BECs. It has been suggested that the altered ergosterol content may influence the composition of the
cell wall and the amount or availability of adhesins on the yeast cell surface [98].
Chemical screening of 30,000 compounds by Fazly et al. [99] identified filastatin (56) (Figure 15) as a small
molecule inhibitor of C. albicans adhesion, morphogenesis and pathogenesis. Preliminary tests showed that 56
significantly reduced the adhesion of C. albicans to polystyrene at a concentration of 9 μg/ml. Interestingly, this
compound could also affect adhesion after the C. albicans cells had already bound to polystryene. 56 reduced the
amount of bound cells when added after adhesion, although not as efficiently as when the compound and cells are
co-incubated at the beginning of the experiment. The ability of 56 to inhibit adhesion to monolayers of human
lung epithelial cells was also determined, at the same concentration as the previous test (9 μg/ml). 56 significantly
inhibited the adherence of green fluorescent protein-labeled C. albicans to monolayers of human lung epithelial
cells as determined by fluorescence quantitation and microscopy [99]. The mode of action is unknown, but due to
the multiple activities of filastatin, it is possible that multiple targets exist.
Previous studies showed that cyclooxygenase inhibitors, such as aspirin, caused a significant reduction in fungal
adhesion of fluconazole resistant C. albicans at concentrations between 0.18 and 1.8 mg/ml [100]. Nitric oxide
(NO) has also been shown to affect adhesion of fungi. NO-releasing xerogel surfaces are effective inhibitors of C.
albicans adhesion at concentrations as low as 2 pmol cm-2 s-1 [101]. Madariaga-Venegas et al. [102] combined these
concepts and evaluated the antifungal/antibiofilm effect of a NO-releasing aspirin (NO-ASA; 57) (Figure 15) on
C. albicans isolates from denture stomatitis patients in vitro. The ability of C. albicans to adhere to polystyrene
microtiter plates was evaluated. It was found that 57 (39 μg/ml) caused a decrease in adhesion in all strains tested,
ranging from 20 to 77%. 57 inhibited the adhesion of C. albicans in a concentration-dependent manner, as the
highest tested concentration of 157.6 μg/ml caused the greatest inhibition ranging from 45 to 97%. Interestingly,
it was found that the equivalent concentration of aspirin actually increased adhesion of the fungi to the polystyrene
plate [102]. 57 has no fungicidal activity, so the observed effects are possibly due to inhibition of PGE2 synthesis.
In an in vitro model of denture stomatitis, compound 58 (Figure 15), a novel antifungal molecule, successfully
inhibited the adhesion of C. albicans and the development of a biofilm on denture acrylic surfaces. The viability of
the biofilm was effected by compound 58, with 85% reduction in viability when 58 was added before the 1.5 h
adhesion phase, 66% reduction when added after, and 97% reduction when added before and after the adhesion
phase [103]. This compound is thought to act by causing cell membrane damage.
The effect of sub inhibitory concentrations of gentian violet (59) (Figure 15) on the germ tube formation by
C. albicans and its adherence ability to oral epithelial cells was investigated. At a concentration of 2.4 μg/ml, 59
significantly reduced the adherence ability of C. albicans by 57%, with similar results seen for all strains tested [80].
C. albicans cells were killed at higher concentrations of 59 (78 μg/ml) while adherence ability and germ tube
formation were prevented at subinhibitory concentrations. It is suggested that 59 may inhibit the production of
adhesins or disrupt the adhesins already present on the cell surface.
Tyrosol (60) is an antioxidant present in natural sources, for example virgin olive oil and wine. 60 has been found
to reduce the total biomass and metabolic activity of C. albicans at concentrations of 27.6 mg/ml [104]. Colony-
forming unit quantification and scanning electron microscope (SEM) observations showed that 60 reduced the
number of adhered cells to acrylic surfaces. It was proposed that tyrosol may interfere with the synthesis or expression
of filament-associated adhesins on the surface of the cells.
Many essential oils and extracts from plants have also been found to inhibit adhesion of C. albicans, but their
active compound is generally unknown, as they are composed of complex, unidentified mixtures of both polar and
nonpolar natural compounds [105–109].
Future perspective
In light of the antimicrobial drug resistance crisis, fungal infections are becoming recognized as a complex problem
for global public health [110,111]. Candida spp. are responsible for threatening invasive infections and mucosal
candidiasis that affect millions of people [112,113]. The drugs currently used to treat and manage these conditions
(namely azoles, echinocandins and polyenes) are still clinically effective, although the toxicity of some of them and
the appearance of resistant strains highlight the urgent need for new and improved antifungal agents [114,115]. Since
the adhesion of pathogens to surfaces and host cells is critical to initiate infection, molecules that block this process
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have therapeutic potential. This strategy has been investigated extensively in bacterial infections [116]; however, the
development of inhibitors of C. albicans adhesion has encountered some obstacles. In recent years, antifungal drug
discovery has focused in a better understanding of the molecular mechanisms of fungal infection; virulence factors,
such as fungal cell wall adhesins [29,117], have emerged as promising targets [11,22,71,118]. Antivirulence agents are less
likely to be toxic or impaired by the development of resistance than conventional fungicidal drugs; nonetheless, our
understanding of the role of adhesion in C. albicans virulence mechanisms is still incomplete; this is partly due to
lacking detailed structural knowledge of the fungal molecules involved in these complex processes. This has limited
structure-based inhibitor design, so the discovery of anti-adhesion compounds against C. albicans infections still
rely mainly in random compound screening. Therefore, it is also important to develop robust anti-adhesion assays
that take into account the physiological environments of cellular adhesion and allow for standardized quantification
of activity. An increased awareness of the opportunities that this area of research offers for the discovery of new
antifungal agents has recently prompted some breakthroughs, with several compounds undergoing preclinical and
clinical trials [113]. The identification of new targets, alongside with the discovery of compounds that target more
than one virulence mechanism (i.e., inhibitors of adhesion, morphogenesis and biofilm formation) are promising
leads for the development of the next generation of antifungal drugs [119]. Further work addressing these issues
should continue to exploit the potential of anti-adhesion therapies not only in C. albicans pathogenesis, but also
for infections caused by other fungal pathogens.
Executive summary
Candida albicans infections
• Candida albicans is a major fungal pathogen responsible for mucosal and invasive infections in
immunocompromised hosts.
• Current therapeutic options are limited and often highly toxic, with appearance of resistant strains.
• Targeting adhesion processes of C. albicans may lead to new and improved antifungal therapies.
Disruption of C. albicans adhesion by antibodies & biomolecules
• Lectins, glycoproteins and antibodies are capable of inhibiting adhesion of C. albicans to buccal epithelial cells.
Disruption of C. albicans adhesion by small molecules
• Small molecules (synthetic and from natural sources) may have different mechanisms to inhibit the adhesion of C.
albicans to host cells, which include:
• targeting the biosynthesis of cell wall components (e.g., inhibitors of β-1,6-glucan biosynthesis);
• targeting the localization of GPI-anchored proteins;
• Inhibition of degradative enzyme production (e.g., inhibitors of secreted aspartyl proteases);
• downregulation of genes that encode for adhesins (e.g., polyphenol and anthraquinone derivatives);
• disruption of the fungal cell membrane structure (e.g., quaternary ammonium compounds, nonantibiotic
antimicrobial agents, terpenes and terpenoids);
• use of small molecules that competitively inhibit the interaction between the fungal adhesins and the host cell
receptors (e.g., heterocyclic and carbohydrate derivatives).
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96. Sá NP, Lima CM, Dos Santos JR et al. A phenylthiazole derivative demonstrates efficacy on treatment of the Cryptococcosis & Candidiasis
in animal models. Future Sci. OA 4(6), FSO305–FSO305 (2018).
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